logo
The Absence of an Ideal Observer : Why Some Clinical Trials May Not Be What We Think They Are
Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke
When to Start a Statin Is a Preference-Sensitive Decision
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease : Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies
Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis : A Multicenter Study of 318 Patients
Multicellular Transcriptional Analysis of Mammalian Heart Regeneration
Interferon Regulatory Factor 5 Controls Necrotic Core Formation in Atherosclerotic Lesions by Impairing Efferocytosis
Acute Coronary Syndromes : The Way Forward From Mechanisms to Precision Treatment
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus
Letter by Donzelli Regarding Article, “Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States : Projections From NHANES (National Health and Nutrition Examination Survey)”
Letter by Koh Regarding Article, “Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States : Projections From NHANES (National Health and Nutrition Examination Survey)”
Response by Bress et al to Letters Regarding Article, “Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States : Projections from NHANES (National Health and Nutrition Examination Survey)”